Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
On September 13, 2023, Fairmount Funds Management LLC, a Director and 10% Owner of Dianthus Therapeutics Inc (NASDAQ:DNTH), purchased 24,254 shares of the company.
The former CEO of a biotech that shut down after a patient death in a clinical trial has made his way to a new startup backed by Flagship Pioneering.
Magenta Therapeutics Inc (NASDAQ: MGTA) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction. The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics Inc and trade on the Nasdaq under the ticker symbol DNTH. Magenta's stockholders will own about 2
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical dat
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect t
Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics are included in this Analyst Blog.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
In the midst of exploring a sale, Magenta Therapeutics Inc. is laying off the vast majority of its staff, including five executives.
Magenta Therapeutics Inc (NASDAQ: MGTA) has implemented a reduction of the company's workforce by up to 56 positions, or approximately 84%, to be substantially completed by February 17, 2023. Hence, the company expects to incur estimated severance and related costs of $5.4 million by the end of February 2023. In January, following a patient death, Magenta Therapeutics paused the Phase 1/2 dose-escalation trial of its acute myeloid leukemia (AML) therapy. The fatality occurred at the Cohort 3 lev
A Cambridge biotech is set to become at least the 10th Massachusetts biotech company to shut down since the start of 2022, following the death of a patient in a clinical trial.